Expertise in
34
conditions

Dr. Kevin R. Kelly

Hematology
Los Angeles General Medical Center Foundation Inc.
1200 N State St, 
Los Angeles, CA 
Offers Telehealth
Expertise in
34
conditions
Los Angeles General Medical Center Foundation Inc.
1200 N State St, 
Los Angeles, CA 

Overview

Kevin Kelly is a Hematologist practicing medicine in Los Angeles, California.

Dr. Kelly is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 56 peer reviewed articles and participating in 9 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in TX

Hospital Affiliations

Los Angeles General Medical Center
Keck Hospital Of USC

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Group
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Los Angeles General Medical Center Foundation Inc.
1200 N State St, Los Angeles, CA 90089

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 1B Study of KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Acute Myeloid Leukemia
A Phase 1B Study of KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2026
Intervention Type: Procedure, Drug
Study Drugs: Decitabine, KRT-232
Study Phase: Phase 1
A Phase 1b Study With Expansion Cohort of Escalating Doses of KRT-232 (AMG 232) Administered in Combination With Standard Induction Chemotherapy (Cytarabine and Idarubicin) in Newly Diagnosed Acute Myelogenous Leukemia (AML)
A Phase 1b Study With Expansion Cohort of Escalating Doses of KRT-232 (AMG 232) Administered in Combination With Standard Induction Chemotherapy (Cytarabine and Idarubicin) in Newly Diagnosed Acute Myelogenous Leukemia (AML)
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2026
Intervention Type: Drug
Study Drugs: Cytarabine, Idarubicin Hydrochloride, Navtemadlin
Study Phase: Phase 1
Phase 1B/II Study of Escalating Doses of Pevonedistat (TAK-924, Formerly MLN4924) Administered in Combination With Standard Induction Chemotherapy (Cytarabine and Idarubicin) in Newly Diagnosed High Risk Acute Myelogenous Leukemia (AML)
Phase 1B/II Study of Escalating Doses of Pevonedistat (TAK-924, Formerly MLN4924) Administered in Combination With Standard Induction Chemotherapy (Cytarabine and Idarubicin) in Newly Diagnosed High Risk Acute Myelogenous Leukemia (AML)
Enrollment Status: Active_not_recruiting
Publish Date: June 01, 2026
Intervention Type: Drug, Other
Study Drugs: Cytarabine, Idarubicin, Pevonedistat
Study Phase: Phase 1/Phase 2
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
Enrollment Status: Completed
Publish Date: December 23, 2025
Intervention Type: Biological, Drug
Study Drugs: Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine
Study Phase: Phase 2
A Phase 1 Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High Risk Myelodysplastic Syndrome
A Phase 1 Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High Risk Myelodysplastic Syndrome
Enrollment Status: Completed
Publish Date: August 31, 2023
Intervention Type: Drug
Study Drug: CB-5339
Study Phase: Phase 1
A Phase 1b Study of REOLYSIN® (Reovirus Serotype 3 - Dearing Strain) Combined With Standard Doses of Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
A Phase 1b Study of REOLYSIN® (Reovirus Serotype 3 - Dearing Strain) Combined With Standard Doses of Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug, Biological, Other
Study Drugs: Bortezomib, Dexamethasone, Wild-type Reovirus
Study Phase: Phase 1
A Randomized Phase II Trial of MLN4924 (Pevonedistat) With Azacitidine Versus Azacitidine in Adult Relapsed or Refractory Acute Myeloid Leukemia
A Randomized Phase II Trial of MLN4924 (Pevonedistat) With Azacitidine Versus Azacitidine in Adult Relapsed or Refractory Acute Myeloid Leukemia
Enrollment Status: Withdrawn
Publish Date: June 27, 2023
Intervention Type: Drug
Study Drugs: Azacitidine, Pevonedistat
Study Phase: Phase 2
View 6 Less Clinical Trials

56 Total Publications

p97 Inhibition Synergistically Enhances Hypomethylating Therapy through Targeting of PLK1 in Acute Myeloid Leukemia.
p97 Inhibition Synergistically Enhances Hypomethylating Therapy through Targeting of PLK1 in Acute Myeloid Leukemia.
Journal: Cancer research communications
Published: January 13, 2026
Similar Doctors
Expertise in
11
conditions
Dr. Thomas D. Coates
Hematology | Oncology
Expertise in
11
conditions
Dr. Thomas D. Coates
Hematology | Oncology
Referral may be required

Office

4650 W Sunset Blvd # 54, 
Los Angeles, CA 
 (5.3 miles away)
323-361-4624
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Thomas Coates is a Hematologist and an Oncologist practicing medicine in Los Angeles, California. Dr. Coates is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Hemoglobinopathy, Anemia, Congenital Hemolytic Anemia, Splenectomy, and Bone Marrow Transplant.

Expertise in
55
conditions
Dr. Stephen J. Forman
Hematology | Oncology
Expertise in
55
conditions
Dr. Stephen J. Forman
Hematology | Oncology
Referral may be required

City Of Hope Comprehensive Cancer Center-Duarte

1500 Duarte Rd, 
Duarte, CA 
 (14.5 miles away)
888-304-3959
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stephen Forman is a Hematologist and an Oncologist practicing medicine in Duarte, California. Dr. Forman is highly rated in 55 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
25
conditions
Expertise in
25
conditions
Referral may be required

USC Norris Comprehensive Cancer Center And Hospital

1441 Eastlake Ave, 
Los Angeles, CA 
 (0.3 miles away)
323-865-3105
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Caroline Piatek is a Hematologist practicing medicine in Los Angeles, California. Dr. Piatek is highly rated in 25 conditions, according to our data. Her clinical expertise encompasses Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Autoimmune Hemolytic Anemia, Splenectomy, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Kevin R. Kelly

How do I make an appointment with Dr. Kevin R. Kelly?

You can book an appointment with Dr. Kevin R. Kelly by calling their office at 323-409-1000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Kevin R. Kelly a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Kevin R. Kelly is classified as an Distinguished expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Kevin R. Kelly specialize in?

While Dr. Kevin R. Kelly is a Hematology, they have specific expertise in Acute Myeloid Leukemia (AML), Multiple Myeloma, and Non-Hodgkin Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Kevin R. Kelly participate in research or clinical trials?

Yes. Dr. Kevin R. Kelly has published 56 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Kevin R. Kelly's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Kevin R. Kelly accept my insurance?

Dr. Kevin R. Kelly accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 323-409-1000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kelly's expertise for a condition
ConditionClose
    View All 28 Advanced Conditions
    View All 37 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile